Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 12: 607641, 2021.
Article in English | MEDLINE | ID: mdl-33936031

ABSTRACT

The Sez6 family consists of Sez6, Sez6L, and Sez6L2. Its members are expressed throughout the brain and have been shown to influence synapse numbers and dendritic morphology. They are also linked to various neurological and psychiatric disorders. All Sez6 family members contain 2-3 CUB domains and 5 complement control protein (CCP) domains, suggesting that they may be involved in complement regulation. We show that Sez6 family members inhibit C3b/iC3b opsonization by the classical and alternative pathways with varying degrees of efficacy. For the classical pathway, Sez6 is a strong inhibitor, Sez6L2 is a moderate inhibitor, and Sez6L is a weak inhibitor. For the alternative pathway, the complement inhibitory activity of Sez6, Sez6L, and Sez6L2 all equaled or exceeded the activity of the known complement regulator MCP. Using Sez6L2 as the representative family member, we show that it specifically accelerates the dissociation of C3 convertases. Sez6L2 also functions as a cofactor for Factor I to facilitate the cleavage of C3b; however, Sez6L2 has no cofactor activity toward C4b. In summary, the Sez6 family are novel complement regulators that inhibit C3 convertases and promote C3b degradation.


Subject(s)
Complement C3-C5 Convertases/metabolism , Complement C3b/immunology , Fibrinogen/metabolism , Membrane Proteins/metabolism , Complement C3b/metabolism , Complement Inactivator Proteins/genetics , Complement Inactivator Proteins/metabolism , Complement Pathway, Alternative/drug effects , Complement Pathway, Classical/drug effects , Gene Expression , Humans , Immunohistochemistry , Membrane Proteins/genetics , Membrane Proteins/pharmacology , Proteolysis , Recombinant Fusion Proteins
2.
Brain Behav Immun ; 87: 739-750, 2020 07.
Article in English | MEDLINE | ID: mdl-32151684

ABSTRACT

Multiple sclerosis (MS) is an inflammatory, neurodegenerative disease of the CNS characterized by both grey and white matter injury. Microglial activation and a reduction in synaptic density are key features of grey matter pathology that can be modeled with MOG35-55 experimental autoimmune encephalomyelitis (EAE). Complement deposition combined with microglial engulfment has been shown during normal development and in disease as a mechanism for pruning synapses. We tested whether there is excess complement production in the EAE hippocampus and whether complement-dependent synapse loss is a source of degeneration in EAE using C1qa and C3 knockout mice. We found that C1q and C3 protein and mRNA levels were elevated in EAE mice. Genetic loss of C3 protected mice from EAE-induced synapse loss, reduced microglial activation, decreased the severity of the EAE clinical score, and protected memory/freezing behavior after contextual fear conditioning. C1qa KO mice with EAE showed little to no change on these measurements compared to WT EAE mice. Thus, pathologic expression and activation of the early complement pathway, specifically at the level of C3, contributes to hippocampal grey matter pathology in the EAE.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Multiple Sclerosis , Neurodegenerative Diseases , Animals , Mice , Mice, Inbred C57BL , Synapses
3.
Glia ; 66(12): 2563-2574, 2018 12.
Article in English | MEDLINE | ID: mdl-30325063

ABSTRACT

Microglial activation, increased proinflammatory cytokine production, and a reduction in synaptic density are key pathological features associated with HIV-associated neurocognitive disorders (HAND). Even with combination antiretroviral therapy (cART), more than 50% of HIV-positive individuals experience some type of cognitive impairment. Although viral replication is inhibited by cART, HIV proteins such as Tat are still produced within the nervous system that are neurotoxic, involved in synapse elimination, and provoke enduring neuroinflammation. As complement deposition on synapses followed by microglial engulfment has been shown during normal development and disease to be a mechanism for pruning synapses, we have tested whether complement is required for the loss of synapses that occurs after a cortical Tat injection mouse model of HAND. In Tat-injected animals evaluated 7 or 28 days after injection, levels of early complement pathway components, C1q and C3, are significantly elevated and associated with microgliosis and a loss of synapses. However, C1qa knockout mice have the same level of Tat-induced synapse loss as wild-type (WT) mice, showing that the C1q-initiated classical complement cascade is not driving synapse removal during HIV1 Tat-induced neuroinflammation.


Subject(s)
Cognitive Dysfunction/pathology , Complement C1q/metabolism , HIV Infections/complications , Synapses/drug effects , tat Gene Products, Human Immunodeficiency Virus/pharmacology , Animals , Bone Marrow/metabolism , Bone Marrow Transplantation , Calcium-Binding Proteins/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Cognitive Dysfunction/etiology , Cognitive Dysfunction/virology , Complement C1q/genetics , Complement C3/pharmacology , Disease Models, Animal , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Gliosis/chemically induced , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microfilament Proteins/metabolism , Microglia/drug effects , Microglia/metabolism , Microglia/pathology , Nerve Tissue Proteins/metabolism , Receptors, Interleukin-8A/genetics , Receptors, Interleukin-8A/metabolism , Synapses/metabolism , Synapses/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...